331 related articles for article (PubMed ID: 24793732)
1. The survival detriment of venous thromboembolism with epithelial ovarian cancer.
Gunderson CC; Thomas ED; Slaughter KN; Farrell R; Ding K; Farris RE; Lauer JK; Perry LJ; McMeekin DS; Moore KN
Gynecol Oncol; 2014 Jul; 134(1):73-7. PubMed ID: 24793732
[TBL] [Abstract][Full Text] [Related]
2. Concomitant venous thromboembolism at the time of primary EOC diagnosis: Perioperative outcomes and survival analyses.
Kumar A; Hurtt CC; Cliby WA; Martin JR; Weaver AL; McGree ME; Langstraat CL; Bakkum-Gamez JN
Gynecol Oncol; 2017 Dec; 147(3):514-520. PubMed ID: 28947173
[TBL] [Abstract][Full Text] [Related]
3. The prognostic significance of preoperative leukocytosis in epithelial ovarian carcinoma: a retrospective cohort study.
So KA; Hong JH; Jin HM; Kim JW; Song JY; Lee JK; Lee NW
Gynecol Oncol; 2014 Mar; 132(3):551-5. PubMed ID: 24440470
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment plasma D-dimer, fibrinogen, and platelet levels significantly impact prognosis in patients with epithelial ovarian cancer independently of venous thromboembolism.
Man YN; Wang YN; Hao J; Liu X; Liu C; Zhu C; Wu XZ
Int J Gynecol Cancer; 2015 Jan; 25(1):24-32. PubMed ID: 25347092
[TBL] [Abstract][Full Text] [Related]
5. A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer.
Suidan RS; St Clair CM; Lee SJ; Barlin JN; Long Roche KC; Tanner EJ; Sonoda Y; Barakat RR; Zivanovic O; Chi DS
Gynecol Oncol; 2014 Sep; 134(3):468-72. PubMed ID: 25042672
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors for maximally or optimally cytoreduced stage III nonserous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy.
Cuylan ZF; Meydanli MM; Sari ME; Akbayir O; Celik H; Dede M; Sahin H; Gungorduk K; Kuscu E; Ozgul N; Gungor T; Ayhan A
J Obstet Gynaecol Res; 2018 Jul; 44(7):1284-1293. PubMed ID: 29727055
[TBL] [Abstract][Full Text] [Related]
7. Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study.
Braicu EI; Fotopoulou C; Van Gorp T; Richter R; Chekerov R; Hall C; Butz H; Castillo-Tong DC; Mahner S; Zeillinger R; Concin N; Vergote I; Sehouli J
Gynecol Oncol; 2013 Feb; 128(2):245-51. PubMed ID: 23178313
[TBL] [Abstract][Full Text] [Related]
8. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of venous thrombosis and tissue factor in epithelial ovarian cancer.
Cohen JG; Prendergast E; Geddings JE; Walts AE; Agadjanian H; Hisada Y; Karlan BY; Mackman N; Walsh CS
Gynecol Oncol; 2017 Jul; 146(1):146-152. PubMed ID: 28501328
[TBL] [Abstract][Full Text] [Related]
10. Neutrophil-to-Lymphocyte Ratio and Platelet Count Predict Long-Term Outcome of Stage IIIC Epithelial Ovarian Cancer.
Zhou M; Li L; Wang X; Wang C; Wang D
Cell Physiol Biochem; 2018; 46(1):178-186. PubMed ID: 29587273
[TBL] [Abstract][Full Text] [Related]
11. Postoperative human epididymis protein 4 predicts primary therapy outcome in advanced epithelial ovarian cancer.
Vallius T; Hynninen J; Auranen A; Matomäki J; Oksa S; Roering P; Grènman S
Tumour Biol; 2017 Feb; 39(2):1010428317691189. PubMed ID: 28218038
[TBL] [Abstract][Full Text] [Related]
12. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
[TBL] [Abstract][Full Text] [Related]
13. Elevated preoperative plasma D-dimer level is a useful predictor of chemoresistance and poor disease outcome for serous ovarian cancer patients.
Liu P; Wang Y; Tong L; Xu Y; Zhang W; Guo Z; Ni H
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1163-71. PubMed ID: 26542279
[TBL] [Abstract][Full Text] [Related]
14. Comparison between serous and non-serous ovarian cancer as a prognostic factor in advanced epithelial ovarian carcinoma after primary debulking surgery.
Hosono S; Kajiyama H; Mizuno K; Sakakibara K; Matsuzawa K; Takeda A; Kawai M; Nagasaka T; Kikkawa F
Int J Clin Oncol; 2011 Oct; 16(5):524-32. PubMed ID: 21431342
[TBL] [Abstract][Full Text] [Related]
15. Pre-operative serum albumin is associated with post-operative complication rate and overall survival in patients with epithelial ovarian cancer undergoing cytoreductive surgery.
Ataseven B; du Bois A; Reinthaller A; Traut A; Heitz F; Aust S; Prader S; Polterauer S; Harter P; Grimm C
Gynecol Oncol; 2015 Sep; 138(3):560-5. PubMed ID: 26163893
[TBL] [Abstract][Full Text] [Related]
16. Venous thromboembolism during primary treatment of ovarian clear cell carcinoma is associated with decreased survival.
Diaz ES; Walts AE; Karlan BY; Walsh CS
Gynecol Oncol; 2013 Dec; 131(3):541-5. PubMed ID: 24041880
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer.
Suidan RS; Leitao MM; Zivanovic O; Gardner GJ; Long Roche KC; Sonoda Y; Levine DA; Jewell EL; Brown CL; Abu-Rustum NR; Charlson ME; Chi DS
Gynecol Oncol; 2015 Aug; 138(2):246-51. PubMed ID: 26037900
[TBL] [Abstract][Full Text] [Related]
18. Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pretreatment Complete Blood Cell Counts in Epithelial Ovarian Cancer.
Paik ES; Sohn I; Baek SY; Shim M; Choi HJ; Kim TJ; Choi CH; Lee JW; Kim BG; Lee YY; Bae DS
Cancer Res Treat; 2017 Jul; 49(3):635-642. PubMed ID: 27669704
[TBL] [Abstract][Full Text] [Related]
19. Venous thromboembolism, interleukin-6 and survival outcomes in patients with advanced ovarian clear cell carcinoma.
Matsuo K; Hasegawa K; Yoshino K; Murakami R; Hisamatsu T; Stone RL; Previs RA; Hansen JM; Ikeda Y; Miyara A; Hiramatsu K; Enomoto T; Fujiwara K; Matsumura N; Konishi I; Roman LD; Gabra H; Fotopoulou C; Sood AK
Eur J Cancer; 2015 Sep; 51(14):1978-88. PubMed ID: 26238017
[TBL] [Abstract][Full Text] [Related]
20. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]